NoduLogic
LUNG NODULE ASSESSMENT

Estimate risk.
Compare with clarity.

One patient profile, validated pre-test models, PET-refined Herder risk, and growth kinetics presented separately for clinical interpretation.

i

Clinical support tool
For use by qualified healthcare professionals. Not a diagnosis or substitute for multidisciplinary clinical judgment.

Risk overview

BPANCAN MODELBrock
0.6%Low

Screening CT model · strongest fit for ages 50–75 with smoking history

MMAYO CLINICMayo
1.4%Low

Incidental solitary nodules · incorporates remote extrathoracic cancer

HPOST–PET-CT MODELHerder
PET neededPending

Select qualitative FDG uptake to calculate PET-refined malignancy probability.

PPKU MODEL · PRIMARILY FOR EAST ASIAN POPULATIONSPeking University
0.5%Low

Surgically resected SPN cohort · includes calcification and border clarity

VGROWTH KINETICSVolume doubling time
Turned offExcluded

Enable interval imaging when a prior diameter and scan interval are available.

!Applicability checks2 items
  • Herder risk is unavailable until qualitative PET-CT uptake is entered.
  • Peking University model: primarily for use in East Asian populations; transportability may vary.
→
BTS PATHWAY · NEXT STEPCT surveillance with growth assessment

With Brock risk below 10%, assess growth using interval CT and automated volumetry where available.

  1. Repeat CT at about 3 months and 1 year for nodules ≥6 mm.
  2. Use ≥25% volume change as significant growth.
  3. The entered diameters imply significant volume growth; verify measurement and consider diagnostic investigation.
BTS Grade C
N
NCCN-ALIGNED SCREENING PATHWAYDiagnostic evaluation

A solid screening nodule of 8 mm or larger generally warrants diagnostic chest CT and consideration of PET-CT and/or tissue sampling according to malignancy probability, comorbidity, and multidisciplinary review.

Screening context only. Initial versus new/growing nodules and solid-component size can change the recommended interval. Verify against the current licensed NCCN guideline.
F
FLEISCHNER SOCIETY 2017 · INCIDENTAL NODULESingle solid nodule 6–8 mm

CT at 6–12 months, then consider CT at 18–24 months; the higher-risk pathway recommends both examinations.

Select timing within the range using clinical and imaging risk factors.
For incidentally detected nodules in adults age 35 or older. Not for lung cancer screening, immunocompromised patients, or patients with known primary cancer.
GUIDELINE-INFORMED SUGGESTED NEXT STEP

Arrange interval CT surveillance

✓
BTSCT surveillance with growth assessment
NCCN screeningNot applicable — incidental finding
Lung-RADSNot applicable — incidental finding
FleischnerSingle solid nodule 6–8 mm
WHAT TO DO NEXT · APPROXIMATELY 6 MONTHS

CT at 6–12 months, then consider CT at 18–24 months; the higher-risk pathway recommends both examinations.

The applicable pathways are directionally aligned for the entered findings.

Recommendation only. The final management decision rests with the treating clinician after review of the complete clinical and imaging context.

Why this recommendation?

Rule applied: FLEISCHNER SOCIETY 2017 · INCIDENTAL NODULE: Single solid nodule 6–8 mm

Why prioritized: The context-specific guideline anchors the recommendation; a more urgent BTS risk-based action takes priority when present.

Information that could change it: age, sex, prior imaging / growth assessment, PET-CT uptake when clinically appropriate

Source versions: BTS pulmonary nodule guideline 2015 · Fleischner Society 2017 · ACR Lung-RADS v2022 · NCCN-aligned screening pathway (verify current licensed edition).

This is a context-aware synthesis, not a new risk score. Use the radiologist’s complete assessment, patient preferences, comorbidity, prior imaging, and multidisciplinary judgment before ordering invasive testing or treatment.

Predicted postoperative FEV₁

—ppoFEV₁
RECOMMENDED NEXT STEPAwaiting inputs

Enter the preoperative FEV₁ percent predicted and the number of functioning lung segments planned for removal.

Use functioning unobstructed segments. This anatomic calculation is intended for lobectomy/segmentectomy; pneumonectomy generally requires perfusion-based calculation. Always calculate ppoDLCO and complete cardiac assessment—ppoFEV₁ alone does not determine operability.

TRANSPARENCY

Built for comparison,
not clinical shortcuts.

Model fit matters
Brock estimates initial CT risk; Mayo is Herder’s pre-test foundation; Herder refines that risk after FDG PET-CT.

VDT is contextual
Growth estimates are sensitive to measurement error, especially in small nodules and when scan intervals are short.

No diagnosis is made
PET can be false-positive in inflammatory disease and false-negative in small or low-metabolism malignancies. Use multidisciplinary judgment.